論文

査読有り
2010年

Combination therapy of lamivudine and interferon-alpha in pediatric patients with chronic hepatitis B in Bangladesh: A safe and effective therapeutic approach for pediatric CHB patients in developing countries

International Journal of Immunopathology and Pharmacology
  • M. Al-Mahtab
  • ,
  • S. Rahman
  • ,
  • Sheikh Mohammad Fazle Akbar
  • ,
  • S. I. Khan
  • ,
  • H. Uddin
  • ,
  • M. F. Karim
  • ,
  • F. Ahmed

23
2
開始ページ
659
終了ページ
664
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1177/039463201002300231
出版者・発行元
Biomedical Research Press s.a.s.

Hepatitis B virus (HBV) is mainly transmitted during birth or perinatal period, however, treatment is not usually recommended for pediatric patients with chronic hepatitis B (CHB). Twelve pediatric patients with CHB in Bangladesh were treated with both lamivudine and interferon. Lamivudine was given at a dose of 3 mg/kg, daily for 12 months. Two months after commencement of lamivudine therapy, all patents were given interferon-α (3 million IU/square meter of body surface area) three times weekly, subcutaneously for 10 months. Combination therapy was safe for all pediatric CHB patients. The levels' of serum HBV DNA became undetectable (&lt
500 copies/ml) in 8 patients and reduced in 4 patients after the end of therapy. Anti-HBe was detected in 10 of 12 patients at this time point. The levels of serum alanine aminotransferase (ALT) were significantly reduced in these patients (p&lt
0.05) due to therapy. Neither flare of HBV DNA nor elevation of serum ALT were detected during follow-up. In conclusion, combination therapy with lamivudine and interferon-α represents a new and novel therapeutic option for treatment of pediatric CHB patients. Copyright © by BIOLIFE, s.a.s.

リンク情報
DOI
https://doi.org/10.1177/039463201002300231
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/20646364
URL
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77955376631&origin=inward

エクスポート
BibTeX RIS